On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies. Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas […]
Learn More
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the “Authorization Term”). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, […]
Learn More
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that innovative drug CMS-D005 injection (“CMS-D005”) self-developed by the Group has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China (“NMPA”) on 27 November 2024. The NMPA grants the Group consent to conduct a clinical trial to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CMS-D005 in healthy and overweight/obese adult subjects in China. CMS-D005 CMS-D005 is a highly active and selective dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Activating glucagon-like peptide-1 (GLP-1) can reduce food intake through central appetite suppression and inhibit gastric emptying to increase satiety to achieve weight loss. Activating GLP-1R can enhance secretion of glucose-dependent insulin and inhibit secretion of glucagon to lower blood glucagon[1], while activating glucagon (GCG) can promote fat catabolism and enhance fat loss, […]
Learn MoreThe news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.
